{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:39:26Z","timestamp":1770989966251,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2013\/09\/NZ4\/02512"],"award-info":[{"award-number":["UMO-2013\/09\/NZ4\/02512"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2018\/29\/N\/NZ3\/02407"],"award-info":[{"award-number":["UMO-2018\/29\/N\/NZ3\/02407"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["RNN\/284\/13\/KE"],"award-info":[{"award-number":["RNN\/284\/13\/KE"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.neo.2020.09.003","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T08:44:02Z","timestamp":1601023442000},"page":"576-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Upregulation of HIF1-\u03b1 via an NF-\u03baB\/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli"],"prefix":"10.1016","volume":"22","author":[{"given":"Dominika","family":"Piasecka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Mieszkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukasz","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Kopczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radzislaw","family":"Kordek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-7299","authenticated-orcid":false,"given":"Rafal","family":"Sadej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna M.","family":"Romanska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2020.09.003_b0005","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0813306106","article-title":"Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast","volume":"106","author":"Hu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2020.09.003_b0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jncimonographs\/lgq019","article-title":"Molecular markers for the diagnosis and management of ductal carcinoma in situ","volume":"2010","author":"Polyak","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.neo.2020.09.003_b0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","article-title":"New horizons in tumor microenvironment biology: challenges and opportunities","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.neo.2020.09.003_b0020","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/onc.2009.416","article-title":"Immune infiltration in human tumors: a prognostic factor that should not be ignored","volume":"29","author":"Pages","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2020.09.003_b0025","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neo.2020.09.003_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2014.0026","article-title":"The role of cytokines in breast cancer development and progression","volume":"35","author":"Esquivel-Velazquez","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.neo.2020.09.003_b0035","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00262-019-02327-7","article-title":"The role of immune infiltrates as prognostic biomarkers in patients with breast cancer","volume":"68","author":"Baxevanis","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.neo.2020.09.003_b0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2326-6066.CIR-19-0786","article-title":"Immune escape during breast tumor progression","volume":"8","author":"Gil Del Alcazar","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.neo.2020.09.003_b0045","article-title":"Metastatic breast cancer: TIL it is too late","author":"Savas","year":"2019","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.neo.2020.09.003_b0050","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/annonc\/mdy399","article-title":"Immunological differences between primary and metastatic breast cancer","volume":"29","author":"Szekely","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neo.2020.09.003_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-10-0372","article-title":"Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers","volume":"9","author":"Camp","year":"2011","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0060","first-page":"4247","article-title":"Distribution and prognostic value of tumorinfiltrating T cells in breast cancer","volume":"18","author":"Meng","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.neo.2020.09.003_b0065","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1541-7786.MCR-11-0604","article-title":"Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages","volume":"10","author":"Stewart","year":"2012","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-12-134","article-title":"Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers","volume":"12","author":"Droeser","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neo.2020.09.003_b0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-07-1127","article-title":"Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution","volume":"14","author":"Allred","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0080","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/onc.2011.279","article-title":"Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling","volume":"31","author":"Pradeep","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2020.09.003_b0085","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJM198811103191902","article-title":"Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer","volume":"319","author":"van de Vijver","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2020.09.003_b0090","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2559.2006.02403.x","article-title":"HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry","volume":"48","author":"Park","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.neo.2020.09.003_b0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/00313020410001692558","article-title":"Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study","volume":"36","author":"Provenzano","year":"2004","journal-title":"Pathology"},{"key":"10.1016\/j.neo.2020.09.003_b0100","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0959-8049(01)00165-4","article-title":"Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics","volume":"37","author":"Ringberg","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neo.2020.09.003_b0105","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1055-9965.EPI-08-1101","article-title":"HER-2\/neu overexpression as a predictor for the transition from in situ to invasive breast cancer","volume":"18","author":"Roses","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.neo.2020.09.003_b0110","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.MP.0000038462.62634.B1","article-title":"The role of HER2\/neu overexpression\/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast","volume":"15","author":"Latta","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.neo.2020.09.003_b0115","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/1471-2407-10-653","article-title":"Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study","volume":"10","author":"Zhou","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neo.2020.09.003_b0120","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12885-015-1479-3","article-title":"The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study","volume":"15","author":"Borgquist","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neo.2020.09.003_b0125","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/path.4840","article-title":"Genome evolution in ductal carcinoma in situ: invasion of the clones","volume":"241","author":"Casasent","year":"2017","journal-title":"J Pathol"},{"key":"10.1016\/j.neo.2020.09.003_b0130","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1158\/0008-5472.CAN-09-4330","article-title":"Tetraspanin CD151 regulates growth of mammary epithelial cells in three-dimensional extracellular matrix: implication for mammary ductal carcinoma in situ","volume":"70","author":"Novitskaya","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0135","doi-asserted-by":"crossref","first-page":"13731","DOI":"10.18632\/oncotarget.3803","article-title":"Development and characterisation of a 3D multi-cellular in vitro model of normal human breast: a tool for cancer initiation studies","volume":"6","author":"Nash","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2020.09.003_b0140","doi-asserted-by":"crossref","unstructured":"Sinn HP, Kreipe H (2013). A brief overview of the WHO classification of breast tumors, 4th Edition, Focusing on issues and updates from the 3rd Edition, Breast Care (Basel) 8, 149-154.","DOI":"10.1159\/000350774"},{"key":"10.1016\/j.neo.2020.09.003_b0145","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod Pathol"},{"key":"10.1016\/j.neo.2020.09.003_b0150","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society Of Clinical Oncology\/College Of American Pathologists Clinical Practice Guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.neo.2020.09.003_b0155","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1309\/VE7862V2646BR6EX","article-title":"HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring","volume":"121","author":"Lal","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.neo.2020.09.003_b0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neo.2020.09.003_b0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.neo.2020.09.003_b0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.neo.2020.09.003_b0175","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neo.2020.09.003_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152500","article-title":"The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis","volume":"11","author":"Mao","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neo.2020.09.003_b0185","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Greulich","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2020.09.003_b0190","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1128\/MCB.01514-06","article-title":"The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo","volume":"27","author":"Yan","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.neo.2020.09.003_b0195","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neo.2017.07.006","article-title":"FGFR2-driven signaling counteracts tamoxifen effect on ER\u03b1-positive breast cancer cells","volume":"19","author":"Turczyk","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.neo.2020.09.003_b0200","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1158\/0008-5472.CAN-09-3497","article-title":"Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis","volume":"70","author":"Sadej","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.trsl.2018.12.007","article-title":"Tetraspanin CD151 impairs heterodimerization of ErbB2\/ErbB3 in breast cancer cells","volume":"207","author":"Mieszkowska","year":"2019","journal-title":"Transl Res"},{"key":"10.1016\/j.neo.2020.09.003_b0210","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1186\/s12885-015-1546-9","article-title":"M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide","volume":"15","author":"Genin","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neo.2020.09.003_b0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00011-007-6115-5","article-title":"Optimized THP-1 differentiation is required for the detection of responses to weak stimuli","volume":"56","author":"Park","year":"2007","journal-title":"Inflamm Res"},{"key":"10.1016\/j.neo.2020.09.003_b0220","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/187152506777698344","article-title":"Cytokines and hormones in the regulation of hypoxia inducible factor-1alpha (HIF-1alpha)","volume":"4","author":"Zhou","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.neo.2020.09.003_b0225","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1389450053765888","article-title":"Small molecules with EGFR-TK inhibitor activity","volume":"6","author":"Albanell","year":"2005","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.neo.2020.09.003_b0230","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1096\/fj.03-0329fje","article-title":"IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB\/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis","volume":"17","author":"Jung","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.neo.2020.09.003_b0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/cbt.8.1.7079","article-title":"Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2","volume":"8","author":"Stasinopoulos","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.neo.2020.09.003_b0240","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/0008-5472.CAN-08-2470","article-title":"Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH","volume":"69","author":"Chiche","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0245","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1016\/j.molimm.2006.12.004","article-title":"Magnolol suppresses NF-kappaB activation and NF-kappaB regulated gene expression through inhibition of IkappaB kinase activation","volume":"44","author":"Tse","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.neo.2020.09.003_b0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-007-9798-y","article-title":"NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells","volume":"111","author":"Zhou","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.neo.2020.09.003_b0255","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1541-7786.632.2.11","article-title":"Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer","volume":"2","author":"Basu","year":"2004","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0260","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/0008-5472.CAN-15-2770","article-title":"STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis","volume":"76","author":"Jones","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0265","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2009.06.018","article-title":"CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages","volume":"16","author":"DeNardo","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2020.09.003_b0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","article-title":"Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast","volume":"161","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.neo.2020.09.003_b0275","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/annonc\/mdw623","article-title":"The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","volume":"28","author":"Pruneri","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neo.2020.09.003_b0280","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","article-title":"Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast","volume":"31","author":"Toss","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.neo.2020.09.003_b0285","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1073\/pnas.1108781108","article-title":"Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling","volume":"109","author":"Kristensen","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2020.09.003_b0290","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/bjs.10127","article-title":"Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer","volume":"103","author":"Asano","year":"2016","journal-title":"Br J Surg"},{"key":"10.1016\/j.neo.2020.09.003_b0295","doi-asserted-by":"crossref","unstructured":"Tawara K, Scott H, Emathinger J, Ide A, Fox R, Greiner D, LaJoie D, Hedeen D, Nandakumar M, Oler AJ, et al. (2019). Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion12, Vol. 12, pp. 245\u2013255.","DOI":"10.1016\/j.tranon.2018.10.004"},{"key":"10.1016\/j.neo.2020.09.003_b0300","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-17-2761","article-title":"HER2 overexpression triggers an IL-1\u03b1 pro-inflammatory circuit to drive tumorigenesis and promote chemotherapy resistance","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2020.09.003_b0305","doi-asserted-by":"crossref","first-page":"15865","DOI":"10.1074\/jbc.M112.426999","article-title":"The oncogene HER2\/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance","volume":"288","author":"Whelan","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neo.2020.09.003_b0310","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.18632\/oncotarget.2806","article-title":"Hypoxia\/HIF1alpha induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2","volume":"6","author":"Karakashev","year":"2015","journal-title":"Oncotarget"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558620301494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558620301494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:07:31Z","timestamp":1761484051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558620301494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1476558620301494"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2020.09.003","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upregulation of HIF1-\u03b1 via an NF-\u03baB\/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2020.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}